(Q35108386)

6 August 2017

Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma (English)

1 reference

6 August 2017

0 references

1 reference

M Miyamoto

1

1 reference

6 August 2017

H Ojima

2

1 reference

6 August 2017

M Iwasaki

3

1 reference

6 August 2017

H Shimizu

4

1 reference

6 August 2017

A Kokubu

5

1 reference

6 August 2017

N Hiraoka

6

1 reference

6 August 2017

T Kosuge

7

1 reference

6 August 2017

D Yoshikawa

8

1 reference

6 August 2017

T Kono

9

1 reference

6 August 2017

H Furukawa

10

1 reference

6 August 2017

T Shibata

11

1 reference

6 August 2017

language of work or name

English

0 references

publication date

14 June 2011

1 reference

British Journal of Cancer

6 August 2017

1 reference

6 August 2017

105

1 reference

6 August 2017

1

1 reference

6 August 2017

131-138

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.2011.199

6 August 2017

0 references

cites work

Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137414

Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137414

Novel therapeutic inhibitors of the c-Met signaling pathway in cancer

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137414

Evidence-based approach to cholangiocarcinoma: a systematic review of the current literature.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137414

Resistance to EGF-R (erbB-1) and VEGF-R modulating agents

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137414

Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137414

Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137414

c-Met targeted therapy of cholangiocarcinoma

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137414

Systemic therapy for biliary tract cancers

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137414

Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137414

Cholangiocarcinoma: natural history, treatment, and strategies for surveillance in high-risk patients

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137414

Signaling networks assembled by oncogenic EGFR and c-Met

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137414

The Met tyrosine kinase receptor in development and cancer

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137414

Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137414

Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137414

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137414

Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137414

The HGF receptor c-Met is overexpressed in esophageal adenocarcinoma.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137414

Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137414

Cholangiocarcinoma: recent progress. Part 1: epidemiology and etiology

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137414

Met receptor tyrosine kinase: enhanced signaling through adapter proteins

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137414

Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137414

Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137414

The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137414

Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137414

c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma.

9 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.199

Prognostic significance of c-Met expression in glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.199

c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.199

Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.199

[Study of gastric carcinoma and PCNA and c-met gene abnormality].

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137414

The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3137414

c-met mRNA overexpression in human hepatocellular carcinoma

27 September 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.199

Chronic Bile Duct Injury Associated with Fibrotic Matrix Microenvironment Provokes Cholangiocarcinoma in p53-Deficient Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.199

Overexpression of c-Met and of the transducers PI3K, FAK and JAK in breast carcinomas correlates with shorter survival and neoangiogenesis

21 January 2018

1 reference

12 December 2020

Increasing incidence of cholangiocarcinoma in Crete 1992-2000

1 reference

12 December 2020

c-met mRNA overexpression in human hepatocellular carcinoma

1 reference

12 December 2020

Expression of the c-met protooncogene in human hepatocellular carcinoma

1 reference

12 December 2020

Clinical significance of hepatocyte growth factor and c-Met expression in extrahepatic biliary tract cancers

1 reference

12 December 2020

c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion

1 reference

12 December 2020

Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells

1 reference

12 December 2020

Overexpression of epidermal growth factor and hepatocyte growth factor receptors in a proportion of gastrinomas correlates with aggressive growth and lower curability

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.2011.199

1 reference

6 August 2017

1 reference

6 August 2017

1 reference